SYK vs TBPH: fair value comparison
Stryker Corporation and Theravance Biopharma, Inc. · Updated 2026-10-19
TBPH is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, SYK currently ranks higher by quality score.
| SYK | TBPH | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $277.33 | $17.03 |
| 12-month range | $269.75–$387.46 | $13.57–$20.74 |
| Rank by discount to fair value | #12 of 108 Healthcare | — |
| Rank by quality score | #32 of 301 Healthcare | #33 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: SYK fair value analysis · TBPH fair value analysis